Pharmacotherapy for mild hypertension

Cochrane Database of Systematic Reviews

Volumn 2012, Issue 8, 2012, Pages

  Diao, Diana ^a   Wright, James M ^b   Cundiff, David K ^d   Gueyffier, Francois ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITÉ LYON 1   (France)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; BENDROFLUMETHIAZIDE; CHLOROTHIAZIDE; CHLORTALIDONE; CLONIDINE; HYDRALAZINE; METHYLDOPA; PINDOLOL; PROPRANOLOL; RESERPINE;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BORDERLINE HYPERTENSION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; HUMAN; ISCHEMIC HEART DISEASE; MORBIDITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; ADULT; BLOOD PRESSURE; CORONARY ARTERY DISEASE; HYPERTENSION; META ANALYSIS; MORTALITY; PATIENT COMPLIANCE; STATISTICS; STROKE;

ADULT; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CORONARY DISEASE; HUMANS; HYPERTENSION; MEDICATION ADHERENCE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STROKE;

EID: 84866757705     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD006742.pub2     Document Type: Review

References (82)

1. A report by the Management Committee of the Australian Theraputic Trial in Mild Hypertension. Untreated mild hypertension. Lancet 1982;1(8265):185-91.
2. Abernethy JD. The Australian Therapeutic Trial in Mild Hypertension. Hypertension 1984;6(5):774-6 1984;6(5):774-776.
3. Abernethy JD. The need to treat mild hypertension. Misinterpretation of results from the Australian trial. JAMA 1986;256(22):3134-37.
4. Anonymous. The Australian Therapeutic Trial in Mild Hypertension. Report by the management committee. Lancet 1980;1:1261-1267.
5. Doyle AE. Cardiovascular morbidity and mortality in mild hypertension: The Australian Trial. Journal of Cardiovascular Pharmacology 1985;7(Suppl 2):S10-13.
6. Doyle AE. The Australian Therapeutic Trial in Mild Hypertension. Nephron 1987;47(Suppl 1):115-19.
7. National Heart Foundation of Australia. Treatment of mild hypertension in the elderly. Med J Aust 1981;2:398-402.
8. Parry CA. Australian Therapeutic Trial in Mild Hypertension. [Letter]. Lancet 1980;2(8191):425.
9. Reader R. Australian Therapeutic Trial in Mild Hypertension. Medical Journal of Australia 1984;140(13):752-54.
10. Report by Management committee of the ATTMH. Initial results of the Australian Therapeutic Trial in mild hypertension (ATTMH). Clinical Science 1979;57:449s-452s.
11. Anonymous. Adverse reactions to bendrofluazide and propanolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet 1981;2(8246):539-43.
12. Anonymous. Coronary heart disease in Medical Research Council trial of mild hypertension. Medical Research Council Working Party on Mild Hypertension. British Heart Journal 1988;59(3):364-378.
13. Anonymous. Course of blood pressure in mild hypertension after withdrawal of long term antihypertensive treatment. Medical Research Council Working Party on Mild Hypertension. Brit Med J 1986;293(6553):988-92.
14. Anonymous. Randomised controlled trial of treatment of mild hypertension: design and pilot trial. Report of the Medical Research Council Working party on mild to Moderate Hypertension. Brit Med J 1977;1(6074):1437-40.
15. Anonymous. Stroke and coronary heart disease in mild hypertension: risk factors and the value of treatment. Medical Research Council Working Party on Mild Hypertension. Brit Med J 1988;296(6636):1565-70.
16. Medical Research council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J 1985;291:97-104.
17. Miall WE. Brennan PJ, Mann AH. Medical research Council's Treatment Trial for mild hypertension: an interim report. Clinical Science and Molecular Medicine 1976;51:563s-565s.
18. Peart S. Results of the MRC (UK) trial of drug therapy for mild hypertension. Clinical and Investigative Medicine 1987;10(6):616-20.
19. Peart S. Barnes GR. Briughton PMG. Dollery CT, et al.Comparison of the antihypertensive efficacy and adverse reactions to two doses of bendrofluazide and hydrochlorothiazide and the effect of potassium supplementation on the hypotensive action of bendrofluazide: substudies of the Medical Research Council's trials of treatment of hypertension. Journal of Clinical Pharmacology 1987;27(4):271-77.
20. Applegate WB. Davis BR. Black HR, et al.Prevalence of postural hypotension at baseline in the systolic hypertension in the elderly program (SHEP) cohort. Journal of American Geriatric Society 1991;39:1057-64.
21. Bearden D. Allman R. McDonald R, et al.Age, race, and gender variation in the utilization of coronary artery bypass surgery and angioplasty in SHEP. Journal of the American Geriatric Society 1994;42:1143-49.
22. Black HR. Unger D. Burlando A, et al.Part 6: Baseline physical examination findings.. Hypertension 1991;17(3 (Suppl II)):II-77-II-101. 1991;17(Suppl II):77-101.
23. Borhani NO. Applegate WB. Cutler JA, et al.Part 1: rationale and design. Hypertension 1991;17(Suppl II):2-15.
24. Brittain E. Palensky J. Blood J and Wittes J. Blinded subjective rankings as a method of assessing treatment effect: a large sample example from the systolic hypertension in the elderly program (SHEP). Statistics in Medicine 1997;16:681-93.
25. Curb JD. Lee M. Jensen J, Applegate W. Part 4: baseline medical history findings. Hypertension 1991;17(Suppl II):35-61.
26. Curb JD. Pressel SL. Cutler JA, et al.Effect of diuretic based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. JAMA 1996;276:1886-92.
27. Davis BR. Wittes J. Pressel S, et al.Statistical considerations in monitoring the systolic hypertension in the elderly program (SHEP). Controlled Clinical Trials 1993;14:350-61.
28. Franse LV. Pahor M. Di Bari M, et al.Serum uric acid, diuretic treatment and risk of cardiovascular events in the systolic hypertension in the elderly program. Journal of Hypertension 2000;18:1149-54.
29. Frost PH. Davis BR. Burlando AJ, et al.Serum lipids and incidence of coronary heart disease. Findings from the systolic hypertension in the elderly program. Circulation 1996;94:2381-88.
30. Hall WD. Davis BR. Frost P, et al.Part 7: Baseline laboratory characteristics. Hypertension 1991;17(Suppl II):102-122.
31. Hawkins CM. Isolated systolic hypertension, morbidity and mortality: The SHEP experience. American Journal of Geriatric Cardiology 1993;2(5):25-27.
32. Kostis JB. Allen R. Berkson DM, et al.Correlates of ventricular ectopic activity in isolated systolic hypertension. American Heart Journal 1994;127:112-21.
33. Kostis JB. Davis BR. Cutler J, et al.Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. JAMA 1997;278(3):212-216.
34. Kostis JB. Lacy CR. Hall D, et al.The effect of chlorthalidone on ventricular ectopic activity in patients with isolated systolic hypertension. American Journal of Cardiology 1994;74:464-67.
35. Kostis JB. Prineas R. Curb JD, et al.Part 8: Electrocardiographic characteristics.. Hypertension 1991;17(Suppl II):123-151.
36. Menard J. Day M. Chatellier G, Laragh JH. Some lessons from systolic hypertension in the elderly program (SHEP). American Journal of Hypertension 1992;5:325-30.
37. Newman AB. Tyrrell KS, Kuller LH. Mortality over four years in SHEP participants with a low ankle-arm index. Journal of American Geriatric Society 1997;45:1472-78.
38. Perry HM. Davis BR. Price TR, et al.Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke. JAMA 2000;284(4):465-471.
39. Petrovich H. Byington R. Bailey G, et al.Part 2: screening and recruitment. Hypertension 1991;17(Suppl II):17-23.
40. Probstfield JL. Applegate WB. Borhani NO, et al.The systolic hypertension in the elderly program (SHEP): an intervention trial on isolated systolic hypertension. Clinc and Exper Hypertension-Theory and Practice 1989;A11(5 & 6):973-89.
41. SHEP cooperative Research Group. Rationale and design of a randomized clinical trial on prevention of stroke in isolated systolic hypertension. Journal of Clinical Epidemiology 1988;41(12):1197-1208.
42. SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the SHEP. ACP Journal Club 1991;115(3):65.
43. SHEP cooperative research group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991;265(24):3255-64. [PUBMED: 2046107].
44. Savage PJ. Pressel SL. Curb D, et al.Influence of long-term, low-dose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension. Archives of Internal Medicine 1998;158:741-751. 1998;158:741-751.
45. Vogt TM. Schron E. Pressel S, et al.Part 3: Sociodemographic characteristics. Hypertension 1991;17(Suppl II):24-34.
46. Wassertheil S. Applegate WB. Berge K, et al.Change in depression as a precursor of cardiovascular events. Archives of Internal Medicine 1996;156:553-561.
47. Wasserthell-Smoller S. FannC. Allman RM, et al.Relation of low body mass to death and stroke in the systolic hypertension in the elderly program. Archives of Internal Medicine 2000;160:494-500.
48. Weiler PG. Camel GH. Chiappini M, et al.Part 9: Behavorial characteristics. Hypertension 1991;17(Suppl II):152-161.
49. Wittes J. Davis B. Berge K, et al.Part 10: Analysis. Hypertension 1991;17(Suppl II):162-167.
50. Perry HM Jr, Goldman AI, Lavin MA, Schnaper HW, Fitz AE, et al.Evaluation of drug treatment in mild hypertension: VA-NHLBI feasibility trial. Plan and preliminary results of a two-year feasibility trial for a multicenter intervention study to evaluate the benefits versus the disadvantages of treating mild hypertension. Ann N Y Acad Sci 1978;304:267-92. [PUBMED: 360921].
51. Perry Jr HM, et al.Treatment of mild hypertension. Preliminary results of a two year feasibility trial. Circ Res 1977;40(suppl):1180-87.
52. Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ 1986;293:1145-51.
53. Liu L, Zhang Y, Liu G, Li W, Zhang X, Zanchetti A. The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients. Journal of Hypertension 2005;23:2157-2172.
54. HDFP. Effect of stepped care treatment on the incidence of myocardial infarction and angina pectoris. 5-year findings of the hypertension detection and follow-up program. Hypertension 1984;6(Suppl 1):198-206.
55. HDFP. Five-year findings of the hypertension detection and follow-up program III. Reduction in stroke incidence among persons with high blood pressure. JAMA 1982;247:633-638.
56. HDFP. The effect of treatment on mortality in "mild"hypertension Results of the hypertension detection and follow-up program. N Engl J Med 1982;307:976-980.
57. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the Hypertension Detection and Follow-up Program: I.Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562-71.
58. Hypertension Detection and Follow-up Program Cooperative Group (HDFP). Five-year findings of the hypertension detection and follow-up program II Mortality by race-sex and age. JAMA 1979;247:2572-2576..
59. Medical Research Council Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992;304:405-12.
60. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982 Sep 24;248(12):1465-77.
61. Helgeland A. Treatment of mild hypertension: a five year controlled drug trial. The Oslo study. Am J Med 1980 Nov;69(5):725-32. [PUBMED: 7001898].
62. Helgeland A, Leren P. Oslo study: Treatment of mild hypertension. Nephron 1987;47(Suppl 1):108-110.
63. Helgeland A. Baksaas IA, Leren P. Mild hypertension - early drug treatment or follow-up only? the Oslo study. Acta Medica Scandinavica. Supplementum 1979;626:34-36.
64. Helgeland A. Hjermann I. Holme I, Liren P. Serum triglycerides and serum uric acid in untreated and thiazide-treated patients with mild hypertension. The American Journal of Medicine 1978;64:34-38.
65. Helgeland A. Leren P. Foss OP, et al.Serum glucose levels during long-term observation of treated and untreated men with mild hypertension. The American Journal of Medicine 1984;76:802-805.
66. Holme I. Coronary risk factors and their possible causal role in the development of coronary heart disease. Journal Oslo City Hospital 1982;32:79-105.
67. Holme I. Helgeland A. Hjermann I, et al.Correlates of blood pressure change in middle-aged male mild hypertensives: results from the untreated control group in the Oslo hypertension trial. American Journal of Epidemiology 1988;127(4):742-52.
68. Leren P, Helgeland A. Coronary heart disease and treatment of hypertension. Some Oslo data. The American journal of Medicine 1986;80(Suppl 2A):3-6.
69. Leren P, et al.Oslo hypertension study. Drugs 1986;31(Suppl 1):41-45.
70. Leren P. Eide I. Foss OP, et al.Blood lipids and antihypertensive drugs. Journal of Pharmacology (Paris) 1983;14(Suppl II):217-20.
71. Leren P. Hegeland A. Hjermann I, Holme I. The Oslo study: CHD risk factors, socioeconomic influences, and interventions. American Heart Journal 1983;106:1200-1206.
72. Smith WM. Treatment of mild hypertension: results of a ten-year intervention trial. Circ Res 1977 May;40(5 Suppl 1):I98-105. [PUBMED: 140029].
73. Collins R, Peto R, Macmahon S, Hebert P, et al.Blood pressure, stroke, and coronary heart disease- Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990;335:827-838.
74. Gueyffier F, Froment A, Gouton M. New meta-analysis of treatment trials of hypertension: improving the estimate of therapeutic benefit. J Human Hyperten 1996;10:1-8.
75. Mancia G, Laurent S, Agabiti-Rosei E, et al.Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. Journal of Hypertension 2009;27:1-38.
76. Marchant I, Nony P, Cucherat M, Boissel J-P, Thomas SR, et al.The Global Risk Approach Should Be Better Applied in French Hypertensive Patients: A Comparison between Simulation and Observation Studies. PLoS ONE 2011;6(3):e17508. [e17508. doi:10.1371/journal.pone.0017508].
77. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, et al.Health outcomes associated with antihypertensive therapies used as first- line agents. A systematic review and meta-analysis. JAMA 1997;277:739-745.
78. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289(19):2534-2544.
79. Quan A, Kerlikowske K, Gueyffier F, Boissel JP, for the INDANA Investigators. Pharmacotherapy for hypertension in women of different races. Cochrane Database of Systematic Reviews 2000, Issue 3. [DOI: 10.1002/14651858.CD002146].
80. Therapeutics Intitiative. Mild Hypertension- An approach to using evidence in the decision making process. Therapeutics Letter Jan-Feb 2007;62:1-2.
81. Wright JM. Cheng-Han Lee, Chambers KC. Systematic review of antihypertensive therapies: does the evidence assist in choosing a first-line drug?. CMAJ 1999;161:25-32.
82. Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database of Systematic Reviews 2009, Issue 3. [DOI: 10.1002/14651858.CD001841].